Patents Assigned to The Liposome Company, Inc.
-
Patent number: 4891208Abstract: Steroidal liposomes comprising a bioactive agent and method for their administration are disclosed, the bilayers of said steroidal liposomes comprising a salt form of a carboxylic acid derivative of a sterol, a salt form of a polycarboxylic acid derivative of a sterol, a salt form of a hydroxy carboxylic acid derivative of a sterol, a salt form of an amino acid derivative of a sterol or a salt form of a poly (amino acid) derivative of a sterol; or a salt form of an organic acid derivative of cholesterol, a vitamin D, a phytosterol, or a steroidal hormone.Type: GrantFiled: September 10, 1985Date of Patent: January 2, 1990Assignee: The Liposome Company, Inc.Inventors: Andrew S. Janoff, Mircea C. Popescu, Alan L. Weiner, Lois E. Bolscak, Paul A. Tremblay, Christine E. Swenson
-
Patent number: 4885172Abstract: The present invention describes a composition consisting of liposomes covalently or non-covalently coupled to the glycoprotein streptavidin. The streptavidin may additionally be coupled to biotinated proteins such as Immunoglobulin G or monoclonal antibodies.The liposomes of the invention may have a transmembrane potential across their membranes, and may be dehydrated. In addition, the composition may contain ionizable bioactive agents such as antineoplastic agents, and may be used in diagnostic assays.Type: GrantFiled: December 15, 1986Date of Patent: December 5, 1989Assignee: The Liposome Company, Inc.Inventors: Marcel B. Bally, Helen Loughrey, Pieter R. Cullis
-
Patent number: 4880635Abstract: Dehydrated liposomes are prepared by drying liposome preparations under reduced pressure in the presence of one or more protective sugars, e.g., the disaccharides trehalose and sucrose. Preferably, the protective sugars are present at both the inside and outside surfaces of the liposome membranes. Freezing of the liposome preparation prior to dehydration is optional. Alternatively, the protective sugar can be omitted if: (1) the liposomes are of the type which have multiple lipid layers; (2) the dehydration is done without prior freezing; and (3) the dehydration is performed to an end point which results in sufficient water being left in the preparation (e.g., at least 12 moles water/mole lipid) so that the integrity of a substantial portion of the multiple lipid layers is retained upon rehydration.Type: GrantFiled: July 26, 1985Date of Patent: November 14, 1989Assignee: The Liposome Company, Inc.Inventors: Andrew S. Janoff, Pieter R. Cullis, Marcel B. Bally, Michael W. Fountain, Richard S. Ginsberg, Michael J. Hope, Thomas D. Madden, Hugh P. Schieren, Regina L. Jablonski
-
Patent number: 4861580Abstract: Methods and compositions are described for the preparation of alpha-tocopherol vesicles, the bilayers of which comprise a salt form of an organic acid derivative of alpha-tocopherol such as the Tris salt form of alpha-tocopherol hemisuccinate. The method is rapid and efficient and does not require the use of organic solvents. The alpha-tocopherol vesicles may be used to entrap compounds which are insoluble in aqueous solutions. Such preparations are especially useful for entrapping bioactive agents of limited solubility, thus enabling administration in vivo.Type: GrantFiled: September 24, 1986Date of Patent: August 29, 1989Assignee: The Liposome Company, Inc.Inventors: Andrew S. Janoff, Lois E. Bolcsak, Alan L. Weiner, Paul A. Tremblay, Michael V. W. Bergamini, Robert L. Suddith
-
Patent number: 4721612Abstract: Methods and compositions are described for the preparation of lipid vesicles, the bilayers of which comprise a salt form of an organic acid derivative of a sterol such as the tris-salt form of a sterol hemisuccinate. The method is rapid, efficient, and does not require the use of organic solvents. The sterol hemisuccinate vesicles may be used to entrap compounds which are insoluble in aqueous solutions. Such preparations are especially useful for entrapping bioactive agents of limited solubility thus enabling administration in vivo.Type: GrantFiled: April 10, 1985Date of Patent: January 26, 1988Assignee: The Liposome Company, Inc.Inventors: Andrew S. Janoff, Mircea C. Popescu, Alan L. Weiner, Lois E. Bolcsak, Paul S. Tremblay
-
Patent number: 4714571Abstract: A process for the separation and purification of individual phospholipids, especially phosphatidylcholine or lecithin and phosphatidylethanolamine, from mixtures containing members of the sub-class of phosphatides, incorporating methods of solvent extraction appropriate to the scale of the sample and utilizing an acetonitrile, acetonitrile-hydrocarbon, or acetonitrile-fluorocarbon solvent, which exhibit differential solubility properties towards the individual phospholipids.Type: GrantFiled: February 6, 1985Date of Patent: December 22, 1987Assignee: The Liposome Company, Inc.Inventors: Paul A. Tremblay, John J. Kearns
-
Patent number: 4708861Abstract: Compositions and methods for maintaining reservoirs of bioactive agents by sequestering the reservoir in a gel matrix are described. In particular, liposomes containing an entrapped bioactive agent are sequestered in a gel matrix. The resulting liposome-gel compositions may be used in vivo or in vitro to provide for sustained release of the bioactive agent. The gel matrix inhibits the dispersion and clearance of the sequestered liposomes without interfering with the ability of the liposomes to release the entrapped bioactive agent. Furthermore, the rate of release of the bioactive agent from the liposome-gel compositions may be varied by altering the composition of the liposomes and/or gels.Type: GrantFiled: January 31, 1985Date of Patent: November 24, 1987Assignee: The Liposome Company, Inc.Inventors: Mircea C. Popescu, Alan L. Weiner, Sharon S. Carpenter-Green
-
Patent number: 4698299Abstract: Lipid-dependent diagnostic assays are provided wherein the test sample to be assayed is pre-incubated with one or more phospholipids having a hexagonal (H.sub.II) organization, with lipidic particles, or with bilayer-forming lysophospholipids such as monooleoylphosphatidylethanolamine (MOPE). The pre-incubation results in reduced false positives due to antiphospholipid antibodies, such as, lupus anticoagulants, which may be present in the test sample, without changing the overall character, including the normal baseline, of the assay. Surprisingly, in accordance with the invention, it has been found that only hexagonal phospholipids, lipidic particles, and bilayer-forming lysophospholipids can be used, and, in particular, lamellar (bilayer) phospholipids (other than such lysophospholipids) cannot be used. An assay for diagnosing systemic lupus erythematosus (SLE) is also provided.Type: GrantFiled: February 19, 1986Date of Patent: October 6, 1987Assignee: The Liposome Company, Inc.Inventors: Andrew S. Janoff, Joyce Rauch, Colin P. S. Tilcock
-
Patent number: 4668638Abstract: An immunoassay utilizing a novel liposome composition in which there is incorporated a stabilizing or destabilizing component and an antigen. The presence of cognate antibodies in test samples is detected by the alteration of the supramolecular structure of the liposomes resulting in changes in stabilization. Destabilization can be detected, and in certain cases, caused by, the addition of magnesium or calcium ions. Increased stabilization can be detected by the polymerization of bilayer components in response to ultraviolet light. Antibody-antigen interactions at the liposome surface mediate the stabilization/destabilization response.Type: GrantFiled: September 26, 1983Date of Patent: May 26, 1987Assignee: The Liposome Company, Inc.Inventors: Andrew S. Janoff, Marc J. Ostro, Alan L. Weiner, Gerald Weissmann, James R. Seibold
-
Patent number: 4666831Abstract: Improved lipid-dependent diagnostic assays are provided wherein the test sample to be assayed is pre-incubated with one or more phospholipids having a hexagonal (H.sub.II) organization or with lipidic particles. The pre-incubation results in reduced false positives due to anti-phospholipid antibodies, such as, lupus anticoagulants, which may be present in the test sample, without changing the overall character, including the normal baseline, of the assay. Suprisingly, in accordance with the invention, it has been found that only hexagonal phospholipids and lipidic particles can be used, and, in particular, lamellar (bilayer) phospholipids cannot be used. An assay for diagnosing systemic lupus erythematosus (SLE) is also provided.Type: GrantFiled: February 19, 1985Date of Patent: May 19, 1987Assignee: The Liposome Company, Inc.Inventors: Andrew S. Janoff, Joyce Rauch, Colin P. S. Tilcock
-
Patent number: 4610868Abstract: Lipid matrix carriers are described which provide for the sustained release of bioactive agents in vivo or in vitro. The properties of the lipid matrix carriers of the present invention include high entrapment efficiencies; release of entrapped compounds in their active form; biodegradability and avoidance of vascular occlusion in vivo; and avoidance of sequestration of the bioactive agent in the liver and spleen.Type: GrantFiled: March 20, 1984Date of Patent: September 9, 1986Assignee: The Liposome Company, Inc.Inventors: Michael W. Fountain, Steven J. Weiss, John J. Kearns, Alan L. Weiner, Mircea C. Popescu
-
Patent number: 4588578Abstract: A process for the preparation in a monophasic solvent system of a new type of lipid vesicles, called monophasic lipid vesicles (MPVs). MPVs can be made to encapsulate one or more bioactive agents. MPVs are stable during storage and can be used in vivo in the treatment of disease.Type: GrantFiled: August 8, 1983Date of Patent: May 13, 1986Assignee: The Liposome Company, Inc.Inventors: Michael W. Fountain, Steven J. Weiss, Mircea C. Popescu
-
Patent number: 4564599Abstract: An assay for detecting SLE antibodies utilizing a novel liposome composition in which there is entrapped a divalent cation responsive indicator. The presence of such antibodies is detected by their stabilization of the supermolecular structure of the liposomes. Such stabilization can be detected, and in certain cases, caused by, the addition of magnesium or calcium ions.Type: GrantFiled: March 24, 1983Date of Patent: January 14, 1986Assignee: The Liposome Company, Inc.Inventors: Andrew S. Janoff, Marc J. Ostro, Alan L. Weiner, Gerald Weissmann, James R. Seibold
-
Patent number: 4522803Abstract: A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same. SPLVs are stable during storage and can be used in vivo for the sustained release of compounds and in the treatment of disease.Type: GrantFiled: March 24, 1983Date of Patent: June 11, 1985Assignee: The Liposome Company, Inc.Inventors: Robert P. Lenk, Michael W. Fountain, Andrew S. Janoff, Marc J. Ostro, Micrea C. Popescu